Tuspetinib Clinical Trials (2026): 1 Studies for Chronic Myelomonocytic Leukemia & Leukemia, Myeloid, Acute
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Tuspetinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Chronic Myelomonocytic Leukemia & Leukemia, Myeloid, Acute) and 240 total planned enrollment. 1 Tuspetinib clinical trial is actively recruiting at 10 U.S. sites across 7 states. Most recent activity: NCT03850574 (Apr 2027).
Where to Participate: All Tuspetinib Trial Sites in the U.S. (10 sites across 7 states)
Every actively recruiting Tuspetinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | The Kirklin Clinic of UAB Hospital | Birmingham35233 | NCT03850574 | Map |
| CA | University of California Irvine | Irvine92697 | NCT03850574 | Map |
| CA | USC/Norris Comprehensive Cancer Center | Los Angeles90033 | NCT03850574 | Map |
| CA | Stanford Cancer Center | Palo Alto94304 | NCT03850574 | Map |
| CA | University of California, Davis | Sacramento95817 | NCT03850574 | Map |
| CT | Yale University | New Haven06520 | NCT03850574 | Map |
| FL | University of Miami - Miller School of Medicine | Miami33136 | NCT03850574 | Map |
| NC | Duke University Medical Center | Durham27705 | NCT03850574 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT03850574 | Map |
| TX | MD Anderson Cancer Center | Huston77030 | NCT03850574 | — |
Tuspetinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting Tuspetinib clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT03850574 | TUSCANYClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | Leukemia, Myeloid, Acute | 240 | Mar 2019 |
All Tuspetinib trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT03850574 | TUSCANY | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | P1/P2 | recruiting | 240 | Aptose Biosciences Inc. | Mar 2019 |
Tuspetinib clinical trials: frequently asked questions
- How many Tuspetinib clinical trials are there?
- 1 Tuspetinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Tuspetinib clinical trials recruiting in 2026?
- Yes — 1 Tuspetinib trial is actively recruiting in 2026, with 10 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Tuspetinib being studied for?
- Tuspetinib is being studied for Chronic Myelomonocytic Leukemia, Leukemia, Myeloid, Acute, Myelodysplastic Syndrome With Excess Blasts-2, Refractory AML, Relapsed Adult AML. The trials are grouped by indication on this page.
- Who sponsors Tuspetinib clinical trials?
- The lead sponsor across the most Tuspetinib trials is Aptose Biosciences Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tuspetinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: